New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > LUNG NSCLC Locally advanced/Metastatic - amivantamab > LUNG - amivantamab 1050 mg
This regimen is a component of LUNG NSCLC Locally advanced/Metastatic - amivantamab

amivantamab 1050 mg (LUNG NSCLC Locally advanced/Metastatic - amivantamab )

Treatment Overview

Recommended starting dose for body-weight less than 80 kg.

Cycle 1 - 28 days

Cycle length:
28

dexamethasone:

  • Days 1 and 2: dexamethasone premedication is required;
  • Days 8, 15 and 22: dexamethasone premedication may be omitted if no infusion-related reaction occurred during previous infusions.  If dexamethasone is omitted, the clinician may consider ondansetron 8 mg ONE hour prior to amivantamab infusion for antiemetic cover. 

Cycle 2 (and all further cycles) - 28 days

Cycle length:
28

amivantamab:

  • Administer dexamethasone 10 mg IV 45 to 60 minutes prior to amivantamab if an infusion-related reaction occurred during previous infusions.
  • If dexamethasone is administered, ondansetron 8 mg ONE hour prior to amivantamab infusion for antiemetic cover may be omitted.

Cycle details

Cycle 1 - 28 days

Medication Dose Route Days Max Duration
dexamethasone * 10 mg flat dosing intravenous 1, 2, 8,
15, 22		 15 minutes
loratadine * 10 mg oral administration 1, 2, 8,
15, 22
paracetamol 1000 mg flat dosing oral administration 1, 2, 8,
15, 22
amivantamab 350 mg flat dosing intravenous 1 5 hours
amivantamab 700 mg flat dosing intravenous 2 5 hours
amivantamab 1050 mg flat dosing intravenous 8, 15, 22 3 hours
domperidone 10 mg Three times daily oral administration 1

dexamethasone:

  • Days 1 and 2: dexamethasone premedication is required;
  • Days 8, 15 and 22: dexamethasone premedication may be omitted if no infusion-related reaction occurred during previous infusions.  If dexamethasone is omitted, the clinician may consider ondansetron 8 mg ONE hour prior to amivantamab infusion for antiemetic cover. 

Cycle 2 (and all further cycles) - 28 days

Medication Dose Route Days Max Duration
ondansetron 8 mg oral administration 1, 15
loratadine * 10 mg oral administration 1, 15
paracetamol 1000 mg flat dosing oral administration 1, 15
amivantamab 1050 mg flat dosing intravenous 1, 15 2 hours
domperidone 10 mg Three times daily oral administration 1

amivantamab:

  • Administer dexamethasone 10 mg IV 45 to 60 minutes prior to amivantamab if an infusion-related reaction occurred during previous infusions.
  • If dexamethasone is administered, ondansetron 8 mg ONE hour prior to amivantamab infusion for antiemetic cover may be omitted.

Full details

Cycle 1 - 28 days

Day: 1

Medication Dose Route Max duration Details
dexamethasone * 10 mg flat dosing intravenous 15 minutes
Instructions:

45 to 60 minutes prior to amivantamab, or as per institutional practice.
loratadine * 10 mg oral administration
Instructions:

30 to 60 minutes prior to amivantamab.
paracetamol 1000 mg flat dosing oral administration
Instructions:

30 to 60 minutes prior to amivantamab. 
amivantamab 350 mg flat dosing intravenous 5 hours
Instructions:
  • Administer via a sterile, non-pyrogenic, low-protein binding 0.2 micron in-line polyethersulfone (PES) filter.
  • For infusion rates, see Additional details below.
Additional details:
domperidone 10 mg Three times daily oral administration
Instructions:

When required for nausea and/or vomiting.

  • The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.

Day: 2

Medication Dose Route Max duration Details
dexamethasone * 10 mg flat dosing intravenous 15 minutes
Instructions:

45 to 60 minutes prior to amivantamab, or as per institutional practice.
loratadine * 10 mg oral administration
Instructions:

30 to 60 minutes prior to amivantamab.
paracetamol 1000 mg flat dosing oral administration
Instructions:

30 to 60 minutes prior to amivantamab. 
amivantamab 700 mg flat dosing intravenous 5 hours
Instructions:
  • Administer via a sterile, non-pyrogenic, low-protein binding 0.2 micron in-line polyethersulfone (PES) filter.
  • For infusion rates, see Additional details below.
Additional details:

Day: 8

Medication Dose Route Max duration Details
dexamethasone * 10 mg flat dosing intravenous 15 minutes
Instructions:

45 to 60 minutes prior to amivantamab, or as per institutional practice.

  • May be omitted if no previous amivantamb administration reactions. 
  • If dexamethasone is omitted, the clinician may consider ondansetron 8 mg ONE hour prior to amivantamab infusion for antiemetic cover.
loratadine * 10 mg oral administration
Instructions:

30 to 60 minutes prior to amivantamab.
paracetamol 1000 mg flat dosing oral administration
Instructions:

30 to 60 minutes prior to amivantamab. 
amivantamab 1050 mg flat dosing intravenous 3 hours
Instructions:
  • Administer via a sterile, non-pyrogenic, low-protein binding 0.2 micron in-line polyethersulfone (PES) filter.
  • For infusion rates, see Additional details below.
Additional details:

Day: 15

Medication Dose Route Max duration Details
dexamethasone * 10 mg flat dosing intravenous 15 minutes
Instructions:

45 to 60 minutes prior to amivantamab, or as per institutional practice.

  • May be omitted if no previous amivantamab administration reactions. 
  • If dexamethasone is omitted, the clinician may consider ondansetron 8 mg ONE hour prior to amivantamab infusion for antiemetic cover.
loratadine * 10 mg oral administration
Instructions:

30 to 60 minutes prior to amivantamab.
paracetamol 1000 mg flat dosing oral administration
Instructions:

30 to 60 minutes prior to amivantamab. 
amivantamab 1050 mg flat dosing intravenous 3 hours
Instructions:
  • Administer via a sterile, non-pyrogenic, low-protein binding 0.2 micron in-line polyethersulfone (PES) filter.
  • For infusion rates, see Additional details below.
Additional details:

Day: 22

Medication Dose Route Max duration Details
dexamethasone * 10 mg flat dosing intravenous 15 minutes
Instructions:

45 to 60 minutes prior to amivantamab, or as per institutional practice.

  • May be omitted if no previous amivantamab administration reactions. 
  • If dexamethasone is omitted, the clinician may consider ondansetron 8 mg ONE hour prior to amivantamab infusion for antiemetic cover.  
loratadine * 10 mg oral administration
Instructions:

30 to 60 minutes prior to amivantamab.
paracetamol 1000 mg flat dosing oral administration
Instructions:

30 to 60 minutes prior to amivantamab. 
amivantamab 1050 mg flat dosing intravenous 3 hours
Instructions:
  • Administer via a sterile, non-pyrogenic, low-protein binding 0.2 micron in-line polyethersulfone (PES) filter.
  • For infusion rates, see Additional details below.
Additional details:

Cycle 2 (and all further cycles) - 28 days

Day: 1

Medication Dose Route Max duration Details
ondansetron 8 mg oral administration
Instructions:

ONE hour prior to amivantamab infusion. 

  • May be omitted if dexamethasone is administered as premedication for hypersenstivity.
loratadine * 10 mg oral administration
Instructions:

30 to 60 minutes prior to amivantamab. 
paracetamol 1000 mg flat dosing oral administration
Instructions:

30 to 60 minutes prior to amivantamab.
amivantamab 1050 mg flat dosing intravenous 2 hours
Instructions:
  • Administer dexamethasone 10 mg IV 45 to 60 minutes prior to amivantamab if an infusion-related reaction occurred during previous infusions.
  • Administer via a sterile, non-pyrogenic, low-protein binding 0.2 micron in-line polyethersulfone (PES) filter.
  • For infusion rates, see Additional details below.
Additional details:
domperidone 10 mg Three times daily oral administration
Instructions:

When required for nausea and/or vomiting.

  • The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.

Day: 15

Medication Dose Route Max duration Details
ondansetron 8 mg oral administration
Instructions:

ONE hour prior to amivantamab infusion. 

  • May be omitted if dexamethasone is administered as premedication for hypersenstivity.
loratadine * 10 mg oral administration
Instructions:

30 to 60 minutes prior to amivantamab. 
paracetamol 1000 mg flat dosing oral administration
Instructions:

30 to 60 minutes prior to amivantamab.
amivantamab 1050 mg flat dosing intravenous 2 hours
Instructions:
  • Administer dexamethasone 10 mg IV 45 to 60 minutes prior to amivantamab if an infusion-related reaction occurred during previous infusions.
  • Administer via a sterile, non-pyrogenic, low-protein binding 0.2 micron in-line polyethersulfone (PES) filter.
  • For infusion rates, see Additional details below.
Additional details:

Additional details

Section 1: Infusion rates

Table from: Rybrevant New Zealand Datasheet (Accessed 06 August 2024).

Supportive Care Factors

Factor Value
Emetogenicity: Low
Hypersensitivity / Infusion related reaction risk: High - routine premedication recommended

References

Janssen-Cilag (New Zealand) Limited. Rybrevant New Zealand Datasheet 19 February 2024. https://www.medsafe.govt.nz/profs/datasheet/r/rybrevantinf.pdf (Accessed 06 August 2024)

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.